Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Journey Medical Corporation announced that Emrosi™, its FDA-approved prescription drug for treating inflammatory lesions of rosacea, now has access to approximately 85% of commercial lives in the U.S. after securing contracts with all three major group purchasing organizations (GPOs). The company expects this expanded coverage to drive further grow…